Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Scrip Awards
Partnered Content
Scrip Asia 100
Report Store
Ask The Analyst
PItCH
PDF Library
RSS Feeds
Subscribe
Advertise
UsernamePublicRestriction
Tags:
Metabolic Disorders Clinical Trials Commercial

Phase III Data Put Zealand's Dasiglucagon On Track, But Behind Others, For Hypoglycemia Rescue

  • Analysis

Executive Summary

Zealand Pharma stresses fast onset of dasiglucagon, which it plans to file on its own but develop commercially through partnership.

You may also be interested in...



Keeping Track: US FDA Clears Two More Biosimilars, First Non-Injectable Glucagon

The latest drug development news and highlights from our US FDA Performance Tracker.

Zealand Rushes Out Good Safety News On Phase III Dasiglucagon Rescue Pen

Early results confirm dasiglucagon's safety profile with no treatment-induced or treatment-boosted anti-drug antibodies.

Lilly Adds PhIII Intranasal Glucagon To Diabetes Arsenal

Eli Lilly & Co has acquired the worldwide rights to Locemia Solutions' Phase III intranasal glucagon product for the treatment of severe hypoglycemia – which it hopes will be the first needle-free option to gain approval for this indication.

Table

View full table

Topics

Related Companies

Tags:
Metabolic Disorders Clinical Trials Commercial
UsernamePublicRestriction

Register

PL007508

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By